Biosimilar uptake in the United States is limited. It has not been comprehensively studied in Medicare Advantage (MA). We find that filgrastim and infliximab biosimilar uptake is greater in MA compared with Traditional Medicare. Most of the difference is driven by 1 MA insurer, Kaiser. This could be due to strategies implemented at the insurer level.
